Dr. Lu is the founding member of NEXTBio Capital, a newly launched biotech investment firm. Dr. Lu has 20+ years of healthcare investment experience in both public securities and private companies, including her previous tenure as Managing Partner of Vivo Capital, Managing Partner at Lilly Asia Ventures (LAV), and Managing Director at OrbiMed Advisors.
Over her investment career, Dr. Lu served on the boards of over 20 healthcare companies, including Turning Point Therapeutics (TPTX), Crown Bioscience Inc (6554.TT, acquired by JSR Life Sciences), Avedro (AVDR, acquired by Glaukos), Terns Pharmaceuticals (TERN), BlossomHill Therapeutics Inc, Zenas Biopharma, Createrna, Avistone Pharmaceuticals, and Echosens. Dr. Lu also has been extensively involved in the company incubations of ADARx Pharmaceuticals, RiboX Therapeutics, Visirna Inc., Ablaze Pharmaceuticals, Elpiscience, and Ronovo Surgical, among others, and served as founding director at inception. Dr. Lu started her Wall Street career as a biotech analyst at Piper Jaffray & Co. and her scientific career in biotech start-ups in the Bay Area.
Dr. Lu earned a PhD (Bioengineering) from the University of Washington; an MBA from the Haas School of Business at the University of California, Berkeley; and she graduated with honors from Tsinghua University in China.
What is Hongbo Lu's net worth?
The estimated net worth of Hongbo Lu is at least $6.31 million as of September 12th, 2024. Dr. Lu owns 476,190 shares of Arrowhead Pharmaceuticals stock worth more than $6,309,518 as of April 25th. This net worth estimate does not reflect any other investments that Dr. Lu may own. Learn More about Hongbo Lu's net worth.
How do I contact Hongbo Lu?
The corporate mailing address for Dr. Lu and other Arrowhead Pharmaceuticals executives is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. Arrowhead Pharmaceuticals can also be reached via phone at (626) 304-3400 and via email at ir@arrowheadpharma.com. Learn More on Hongbo Lu's contact information.
Has Hongbo Lu been buying or selling shares of Arrowhead Pharmaceuticals?
Hongbo Lu has not been actively trading shares of Arrowhead Pharmaceuticals during the last ninety days. Most recently, on Wednesday, March 20th, Hongbo Lu bought 1,000 shares of Arrowhead Pharmaceuticals stock. The stock was acquired at an average cost of $27.50 per share, with a total value of $27,500.00. Following the completion of the transaction, the director now directly owns 33,680 shares of the company's stock, valued at $926,200. Learn More on Hongbo Lu's trading history.
Who are Arrowhead Pharmaceuticals' active insiders?
Arrowhead Pharmaceuticals' insider roster includes Christopher Anzalone (CEO), Marianne De Backer (Director), Mauro Ferrari (Director), Douglass Given (Director), James Hamilton (Sr. VP of Discovery & Translational Medicine), James Hassard (Insider), Hongbo Lu (Director), Kenneth Myszkowski (CFO), Patrick O'Brien (General Counsel), Tracie Oliver (Insider), Adeoye Olukotun (Director), Javier San Martin (Insider), Victoria Vakiener (Director), and William Waddill (Director). Learn More on Arrowhead Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Arrowhead Pharmaceuticals?
In the last year, insiders at the biotechnology company sold shares 15 times. They sold a total of 434,505 shares worth more than $7,271,437.48. The most recent insider tranaction occured on April, 11th when CEO Christopher Richard Anzalone sold 50,800 shares worth more than $583,692.00. Insiders at Arrowhead Pharmaceuticals own 4.3% of the company.
Learn More about insider trades at Arrowhead Pharmaceuticals. Information on this page was last updated on 4/11/2025.
